Investor relations
Building the HERV medicine company
GeNeuro is now incorporated in the United States and is preparing for its first securities offering under the SEC Reg CF regulations.* The ticker symbol "HERV" has been reserved for us by the US Nasdaq. We are committed to transparent, timely communication with our shareholders and the broader investment community.
*all materials on this website constitute a "testing the waters" communication
Why GeNeuro
The investment thesis
First-mover in HERV biology
GeNeuro holds the foundational IP and clinical data in HERV-targeted therapeutics — a field with no direct competitors at clinical stage.
Platform with multiple shots on goal
The same antibody platform addresses MS, ALS, Psychosis, and T1D — four large, underserved markets with significant unmet need.
De-risked lead asset
Temelimab has completed Phase I and Phase II trials with a well-characterized safety profile and early efficacy signals in MS.
Partnership optionality
GeNeuro is actively seeking co-development and licensing partnerships with major pharmaceutical companies for its lead and pipeline programs.
News
Press releases
GeNeuro reports positive Phase II data for temelimab in progressive MS
GeNeuro announces expansion of HERV-W program into Type 1 Diabetes
GeNeuro presents ALS preclinical data at Society for Neuroscience annual meeting
GeNeuro completes CHF 15M financing round to advance clinical programs
Get in touch
Investor contact
For investor inquiries, analyst briefings, or to request our latest investor presentation, please use the form below or contact us directly.